Kennedy Capital Management LLC Takes $4.66 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Kennedy Capital Management LLC bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 159,288 shares of the biopharmaceutical company’s stock, valued at approximately $4,658,000. Kennedy Capital Management LLC owned 0.28% of Agios Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Agios Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after acquiring an additional 44,583 shares in the last quarter. Armistice Capital LLC increased its position in shares of Agios Pharmaceuticals by 6.0% in the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock valued at $78,479,000 after acquiring an additional 200,000 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Agios Pharmaceuticals by 5.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock valued at $57,832,000 after acquiring an additional 137,873 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after buying an additional 388,381 shares during the period. Finally, First Trust Advisors LP raised its stake in Agios Pharmaceuticals by 2.4% in the fourth quarter. First Trust Advisors LP now owns 1,818,643 shares of the biopharmaceutical company’s stock valued at $40,501,000 after buying an additional 43,476 shares during the period.

Agios Pharmaceuticals Stock Down 1.3 %

NASDAQ:AGIO traded down $0.64 during midday trading on Tuesday, hitting $46.79. The company had a trading volume of 373,835 shares, compared to its average volume of 790,339. The stock’s fifty day moving average price is $43.48 and its 200-day moving average price is $34.00. Agios Pharmaceuticals, Inc. has a 52-week low of $19.80 and a 52-week high of $50.35. The company has a market capitalization of $2.66 billion, a PE ratio of -7.43 and a beta of 0.78.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.20. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The company had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.37 million. During the same period in the prior year, the firm earned ($1.47) earnings per share. Agios Pharmaceuticals’s revenue was up 46.0% on a year-over-year basis. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -2.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AGIO shares. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research note on Tuesday, June 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $50.67.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.